TCIM
XFOR icon

TIAA CREF Investment Management’s X4 Pharmaceuticals XFOR Stock Holding History

TIAA CREF Investment Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$174K Buy
333
+205
+160% +$113K ﹤0.01% 2908
2018
Q4 		$54K Buy
+128
New +$48.8K ﹤0.01% 2996

Other funds holding XFOR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's XFOR Position: Q1 2019 in Review

TIAA CREF Investment Management increased its X4 Pharmaceuticals (XFOR) stake by 160% in Q1 2019, buying an estimated $113K and bringing the position to 333 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

TIAA CREF Investment Management first reported a position in XFOR in Q4 2018 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold XFOR as of Q1 2019.

  • TIAA CREF Investment Management held 333 shares of X4 Pharmaceuticals worth $174K as of Q1 2019.
  • TIAA CREF Investment Management bought 205 X4 Pharmaceuticals shares in Q1 2019, an estimated $113K.
  • X4 Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2908 holding.
  • TIAA CREF Investment Management first reported a position in X4 Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.